Keywords: Prostate, CancerThe first-in-human hyperpolarized [1-13C]pyruvate+[13C,15N2]urea dual-agent MRI demonstrated the safety and feasibility of simultaneous characterization of prostate cancer metabolism and blood flow as a two-minute addition to the standard 1H-multiparametric MRI. Metabolism-perfusion mismatch (i.e. elevated pyruvate-lactate conversion and decreased urea perfusion) in subregions of the high-grade prostate tumor was in agreement with the histopathological and immunochemical markers that reflected lethal phenotypes and their associated hypoxic tumor microenvironment. Correlative analysis of urea and Gadolinium-derived pharmacokinetic parameters found low correlation between the two, which indicates that HP 13C urea’s unique contrast mechanism offers independent information inaccessible through conventional 1H DCE-MRI.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords